Whole glucan particles enhance immune modulation in combination with TIGIT checkpoint blockade through Dectin-1...

科学分野:

• Immunology
• Oncology
• Pharmacology

背景:

• TIGIT (T cell immunoreceptor with Ig and ITIM domains) checkpoint blocking antibodies are an emerging cancer immunotherapy.
• The efficacy of TIGIT blockade alone is often limited in combating tumors.

研究 の 目的:

• To evaluate the efficacy of combining whole glucan particles (WGP), an immune adjuvant, with anti-TIGIT antibody therapy.
• To investigate the underlying immune mechanisms of this combination therapy in preclinical cancer models.

主な方法:

• Combination therapy using WGP and anti-TIGIT antibody was tested in LLC lung and 4T1 breast cancer models.
• Immune profiling included analysis of intratumoral immune cells (T cells, NK cells, macrophages, MDSCs, Tregs), cytokine levels, and serum immunoglobulins.
• Dectin-1 signaling pathways (Syk/NF-κB) and MDSC apoptosis were assessed. Dectin-1 knockout mice were used to confirm WGP's mechanism.

主要な成果:

• The combination therapy significantly reduced tumor burden and prolonged survival compared to monotherapy.
• Enhanced intratumoral CD8+ T and NK cells, M1-like macrophage polarization, and reduced MDSCs and Tregs were observed.
• WGP's adjuvant effect was confirmed to be Dectin-1 dependent, involving myeloid reprogramming and innate-adaptive immune activation.

結論:

• Whole glucan particles (WGP) act as a potent adjuvant, augmenting TIGIT blockade efficacy through Dectin-1-mediated mechanisms.
• This combination therapy represents a promising strategy for cancer treatment by coordinating innate and adaptive immune responses.
• β-glucan-based innate immune priming is a rational approach to enhance TIGIT and other T-cell-directed checkpoint inhibitors.